Cytek Biosciences is a medical devices business based in the US. Cytek Biosciences shares (CTKB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.41 – an increase of 4.57% over the previous week. Cytek Biosciences employs 645 staff and has a trailing 12-month revenue of around $201.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.41 |
|---|---|
| 52-week range | $4.66 - $9.87 |
| 50-day moving average | $5.45 |
| 200-day moving average | $6.11 |
| Wall St. target price | $8.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.69 from 2024-11-25
| 1 week (2024-11-19) | 9.14% |
|---|---|
| 1 month (2024-10-25) | 42.64% |
| 3 months (2024-08-26) | 17.99% |
| 6 months (2024-05-24) | 12.25% |
| 1 year (2023-11-24) | -4.29% |
|---|---|
| 2 years (2022-11-25) | -53.22% |
| 3 years (2021-11-26) | 19.02 |
| 5 years (2019-11-23) | N/A |
| Revenue TTM | $201.2 million |
|---|---|
| Gross profit TTM | $101 million |
| Return on assets TTM | -2.74% |
| Return on equity TTM | -2.54% |
| Profit margin | -5.05% |
| Book value | $2.97 |
| Market Capitalization | $832.1 million |
TTM: trailing 12 months
We're not expecting Cytek Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Cytek Biosciences's shares have ranged in value from as little as $4.66 up to $9.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytek Biosciences's is 1.321. This would suggest that Cytek Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Cytek Biosciences's beta into context you can compare it against those of similar companies.
Cytek Biosciences, Inc. , a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.